Series C is led by Koch Disruptive Technologies and includes Bristol Myers Squibb, DFJ Growth, Willett Advisors and existing investors Eclipse, Decheng Capital, and 8VC Cellares' commercial-scale IDMO ...
− Full-scale CDMO services for collaborating companies designed to facilitate radiopharmaceutical development and commercialization in complex, highly regulated radiopharmaceutical sector – − ...
NOTTINGHAM, England--(BUSINESS WIRE)--Quotient Sciences, the drug development and manufacturing accelerator, announced that it has acquired Arcinova, the U.K.-based multiservice contract development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback